Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01344330
Recruitment Status : Completed
First Posted : April 29, 2011
Last Update Posted : December 19, 2020
Sponsor:
Collaborators:
Oregon Health and Science University
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roderick Dashwood, Texas A&M University

Brief Summary:
This research study will assess cruciferous vegetable intake in patients presenting for screening colonoscopy and correlate intake with histone status and histone deacetylace (HDAC) expression in tissue biopsy specimens and peripheral blood mononuclear cells (PBMCs). The investigators will also measure sulforaphane (SFN) metabolites in blood as a biomarker of cruciferous vegetable intake.

Condition or disease
Colon Cancer

Layout table for study information
Study Type : Observational
Actual Enrollment : 108 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients
Actual Study Start Date : January 2012
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Colonoscopy

Group/Cohort
Screening colonoscopy patients
Men and women age 50 to 75 scheduled for screening colonoscopy



Primary Outcome Measures :
  1. Cruciferous vegetable intake correlated with SFN and I3C urinary metabolites [ Time Frame: At colonoscopy (day 1) ]

Secondary Outcome Measures :
  1. Cruciferous vegetable intake and p21 expression (qRT-PCR, ChIP in PBMCs) [ Time Frame: at colonoscopy ]
  2. Cruciferous vegetable intake correlated with acetylated histone expression (PBMCs, colon tissue), [ Time Frame: at colonoscopy ]
  3. Cruciferous vegetable intake correlated with HDAC activity (in PBMCs) [ Time Frame: at colonoscopy ]

Biospecimen Retention:   Samples Without DNA
Protein lysate and RNA obtained from de-identified normal colon biopsy specimens are stored at -80 degree centigrade.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients scheduled for screening colonoscopy
Criteria

Inclusion criteria:

  • scheduled for screening colonoscopy
  • off NSAID or aspirin therapy in accordance with OHSU endoscopy clinic guidelines
  • INR 0.90-1.20
  • hemoglobin ≥ 13.5 (men) or 12.0 (women)
  • platelets ≥100,000/μL
  • Chem screen results within normal limits
  • negative (serum or urine) pregnancy test done ≤7 days prior to colonoscopy for women of childbearing potential only
  • ASA performance status <2

Exclusion criteria:

  • history of colon cancer or adenomatous polyps
  • current smoker
  • medical history of chronic obstructive pulmonary disease
  • current oral steroid therapy
  • current therapy with valproate or other pharmacological drugs associated with HDAC inhibition
  • use of oral antibiotics within 3 months prior to entry into study
  • significant active medical illness which in the opinion of the investigator would preclude collection/interpretation of colon tissue
  • diagnosis of hemophilia, van Willebrand's disease or other bleeding disorder
  • use of warfarin or other blood thinning agents
  • inflammatory bowel disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01344330


Locations
Layout table for location information
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97201
Sponsors and Collaborators
Texas A&M University
Oregon Health and Science University
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Rod Dashwood, PhD Oregon State University
Layout table for additonal information
Responsible Party: Roderick Dashwood, Professor, Texas A&M HSC, Texas A&M University
ClinicalTrials.gov Identifier: NCT01344330    
Other Study ID Numbers: P01CA090890 ( U.S. NIH Grant/Contract )
P01CA090890 ( U.S. NIH Grant/Contract )
First Posted: April 29, 2011    Key Record Dates
Last Update Posted: December 19, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Group information (High versus Low Cruciferous Vegetable Intake) will be made available. No IPD will be made available.
Keywords provided by Roderick Dashwood, Texas A&M University:
Colon cancer
Prevention
Cruciferous vegetables
Histone status
Additional relevant MeSH terms:
Layout table for MeSH terms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases